<DOC>
	<DOCNO>NCT02928497</DOCNO>
	<brief_summary>The purpose study establish safety effectiveness WATCHMAN™ Left Atrial Appendage Closure ( LAAC ) Device , include post-implant medication regimen , subject non-valvular atrial fibrillation deem eligible anti-coagulation therapy reduce risk stroke .</brief_summary>
	<brief_title>Assessment WATCHMAN™ Device Patients Unsuitable Oral Anticoagulation</brief_title>
	<detailed_description>The ASAP-TOO study prospective , randomize , multi-center , global investigation establish safety effectiveness WATCHMAN Device subject non-valvular atrial fibrillation deem suitable anti-coagulation therapy reduce risk stroke . Subjects randomize ratio 2 Device 1 Control receive WATCHMAN LAA closure device ( Device ) control treatment single antiplatelet medication medication discretion study physician ( Control ) . All randomized subject follow protocol require test assessment schedule follow-up visit .</detailed_description>
	<criteria>The subject legal age participate study per law respective geography . The subject document paroxysmal , persistent , permanent longterm/longstanding persistent nonvalvular atrial fibrillation ( i.e. , subject diagnose rheumatic mitral valvular heart disease ) . The subject calculate CHA2DS2VASc score 2 great . The subject deem two study physician unsuitable oral anticoagulation . The subject deem study physician suitable define protocol pharmacologic regimen aspirin clopidogrel therapy follow WATCHMAN Closure Device implant . The subject legal representative able understand willing provide write informed consent participate trial . The subject able willing return require followup visit examination . The subject unable unwilling return require followup visit examination . The subject plan invasive cardiac procedure within 30 day prior randomization ( e.g. , cardioversion , ablation ) . The subject planning cardiac noncardiac invasive surgical procedure would necessitate stop modify protocol require medication regimen within 90 day WATCHMAN Closure Device implant ( e.g. , cardioversion , ablation , cataract surgery ) . The subject prior stroke ( cause ) TIA within 30 day prior randomization . The subject prior BARC type 3 4 bleeding event within 14 day prior randomization . Lack resolution relate clinical sequela , plan pending intervention resolve bleeding/bleeding source , exclusion regardless time bleed event . The subject history atrial septal repair ASD/PFO device . The subject implant mechanical valve prosthesis position . The subject suffer New York Heart Association Class IV Congestive Heart Failure . The subject LVEF &lt; 30 % . The subject childbearing potential , plan become pregnant time study ( method assessment upon study physician 's discretion ) . The subject currently enrol another investigational study registry would directly interfere current study , except subject participate mandatory governmental registry , purely observational registry associate treatment . Each instance bring attention sponsor determine eligibility . The subject life expectancy less two year . The subject know suspect hypercoagulable state .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>Left atrial appendage</keyword>
</DOC>